Knowledge Hub

Dysmenorrhea - Pipeline Review, H1 2015

Press Release   •   Nov 07, 2016 06:19 EST has recently announced the addition of a market study “ Dysmenorrhea - Pipeline Review, H1 2015 ”, is a comparative analysis of the global market.

Global Markets Directs, Dysmenorrhea Pipeline Review, H1 2015, provides an overview of the Dysmenorrheas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dysmenorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dysmenorrhea and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


The report provides a snapshot of the global therapeutic landscape of Dysmenorrhea

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Dysmenorrhea and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Dysmenorrhea pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Download The sample Copy Of This Report:

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Dysmenorrhea

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Dysmenorrhea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Dysmenorrhea Overview 6

Therapeutics Development 7

Pipeline Products for Dysmenorrhea - Overview 7

Pipeline Products for Dysmenorrhea - Comparative Analysis 8

Dysmenorrhea - Therapeutics under Development by Companies 9

Dysmenorrhea - Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Dysmenorrhea - Products under Development by Companies 12

Dysmenorrhea - Companies Involved in Therapeutics Development 13

Merck & Co., Inc. 13

ObsEva SA 14

PDC Biotech GmbH 15

Thar Pharmaceuticals, Inc. 16

Dysmenorrhea - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

MK-8342B - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

OBE-002 - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

PDC-41 - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Peptidometics - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

T-109 - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Dysmenorrhea - Dormant Projects 31

Dysmenorrhea - Discontinued Products 32